European stock markets closed mixed in Monday trading, with investors remaining on the sidelines as they weighed geopolitical concerns and mulled last week's tech route.
The Stoxx Europe 600 edged 0.1% higher, Germany's DAX declined 0.1%, the FTSE 100 lost 0.1%, France's CAC fell 0.6%, and the Swiss Market Index gained 0.3%.
In corporate news, Eni has started enhanced gas production off the coast of Libya, in partnership with Libyan National Oil, the Italian integrated energy producer said Monday.
Eni also disclosed that the Sabratha Compression Project, an offshore development designed to sustain and increase gas output from the Bahr Essalam gas field, is operational.
Shares of the oil and gas major rose 1.5% in Milan.
AstraZeneca's Enhertu has been approved by the European Commission for treating adults with previously treated HER2-positive unresectable or metastatic solid tumors who have no satisfactory treatment options.
The approval was based on phase 2 studies showing clinically meaningful response rates in patients with HER2-positive tumors across multiple cancer types, it said.
Shares of the pharmaceutical company edged 0.1% lower in London.
British American Tobacco's Fit2Win transformation program is on track to deliver 600 million British pounds ($792.5 million) in annual cost savings by 2028, impacting about 9,000 roles globally, the company said Monday.
The program was launched in 2025, covering initiatives to streamline the company's operations and build partnerships with technology and business services providers like Accenture, according to the statement.
Shares of the tobacco company declined 0.7% in London.